lthreosphingosine c18

L-threo-Sphingosine C-18 is a protein kinase C inhibitor.

C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancers [1].

PAF C-18 is a naturally occurring phospholipid produced upon stimulation through two distinct pathways known as the remodeling and 'de novo' pathways. It is less potent than PAF C-16 in the induction of platelet aggregation

C18 Phytoceramide (t18:0 18:0) (Cer(t18:0 18:0)) is a bioactive sphingolipid found in S. cerevisiae, wheat grains, and the stratum corneum layer of mammalian epidermis. It comprises a phytosphingosine backbone amine-linked to a C18 fatty acid chain. Cer(t18:0 18:0) regulates apoptosis, cell differentiation, smooth muscle cell proliferation, and inhibits the mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated murine skin tissue. Formulations with cer(t18:0 18:0) are utilized in cosmetics as skin protectants, reducing water loss and preventing epidermal dehydration and irritation.

C18 L-threo Ceramide is a synthetic ceramide and stereoisomer of C18 ceramide that has been used for structural characterization of natural sphingolipids. It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.21 mol% (16.8 μM).

C18 L-erythro Ceramide (d18:1/18:0) significantly reduced extracellular Aβ levels and can be used to study Alzheimer's disease.

PAF C-18:1 is a naturally occurring phospholipid produced by cells upon stimulation and plays a role in the establishment and maintenance of the inflammatory response. It is less potent than PAF C-16 and PAF C-18 in the induction of neutrophil chemotaxis, but is equipotent to PAF C-16 and PAF C-18 in promoting eosinophil migration. PAF C-18:1 activates the PAF receptor and has been used in antibody binding experiments to determine the importance of an acyl linkage at the sn-2 position for recognition at this receptor.

C18 Ceramide-1-phosphate (d18:1 18:0) is a long-chain molecule identified in murine skin, promoting the migration of mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells (HUVECs) at concentrations of 0.5 to 5 µM. It exhibits elevated levels in CFPAC-1 pancreatic ductal adenocarcinoma cells compared to pancreatic cancer stem cells, and its myocardial concentration is heightened in Langendorff isolated perfused mouse hearts under an ex vivo ischemia model.

C18:1 Ceramide is a naturally occurring ceramide.[1][2][3] Levels of C18:1 ceramide are elevated in overweight and insulin-resistant mice and cattle.[1][2] C18:1 Ceramide is also increased in the plasma and ovarian tissue of patients with advanced ovarian cancer. [3]

C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. [1] Increased C18 dihydroceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes. [2] It is also elevated in the skin of patients with lesional atopic dermatitis.[3]

C18 D-threoCeramide (d18:1/18:0) is a synthetic ceramide and stereoisomer of C18 ceramide .1It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50value of 16.6 μM.2[Matreya, LLC. Catalog No. 1855] 1.Koolath, S., Murai, Y., Suga, Y., et al.Chiral combinatorial preparation and biological evaluation of unique ceramides for inhibition of sphingomyelin synthaseChirality32(3)308-313(2019) 2.Usta, J., El Bawab, S., Roddy, P., et al.Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidaseBiochemistry40(32)9657-9668(2001)

C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. Levels of short-chain sulfatides, including C18 3'-sulfo galactosylceramide, decrease with age in mice and humans. It is increased in brain from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions. Plasma levels of C18 3'-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale. It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).

C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide . It inhibits aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate (PMA; 10008014) when used at a concentration of 1 μM. C18 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. C18 globotriaosylceramide also accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease.

C18:1 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It has been found in mouse brain. It has been used as a standard for the quantification of C18:1 3'-sulfo galactosylceramide in dried blood spots from patients with metachromatic leukodystrophy (MLD) by UPLC-MS.